Patients with bone metastatic cancer
Conditions
Interventions
Gammadelta T cell Radiation Zoledronate
Sponsors
University of Tokyo, Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with bone metastatic cancer - Performance status 0-1 - No serious abnormality in bone marrow, liver and renal functions
Exclusion criteria
Exclusion criteria: Patients who have: out-of-controlled infections, active autoimmune diseases, serious complications, other cancers, active enteritis, and symptoms of fibroid lung or interstitial pneumonia; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Antitumor effects on the metastatic foci and primary lesion; Time to progression; Improvement of tumor-related markers, and immunological parameters. | — |
Countries
Japan
Contacts
Public ContactKazuhiro Kakimi
University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics (medinet)
Outcome results
None listed